Abstracts tagged "Compliance"

Abstract Number: 2268 • 2017 ACR/ARHP Annual Meeting
Patient Perspectives from a Qualitative Study Predict Non-Adherence in Rheumatoid Arthritis
Valentin Ritschl^1,2, Angelika Lackner³, Carina Boström⁴, Michael Kundi⁵, Michaela Lehner⁶, Paul Studenic⁷, Winfried Graninger⁸, Josef S. Smolen⁹ and Tanja Stamm¹⁰, ¹Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ²Section Occupational Therapy, Department Health Sciences, FH Campus Wien, Vienna, Austria, Vienna, Austria, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁴Division of Physiotherapy, Department of Neurobiology, Karolinska Institutet, Huddinge, Sweden, Stockholm, Sweden, ⁵Center for Public Health, Department of Environmental Health, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ⁷Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁸Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹⁰Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Vienna, Austria
Background/Purpose: In rheumatoid arthritis (RA), up to 80% of patients were found to be non-adherent to prescribed medication and non-pharmacological interventions. These patients do not…
Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Seong-Min Kweon¹, Seung-Geun Lee², Ji-Heh Park², Eun-Kyoung Park³, Yun-Kyung Kim⁴, Geun-Tae Kim⁵ and Dong Hyun Sohn⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ²Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁴Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁵Kosin University College of Medicine, Busan, Korea, Republic of (South), ⁶Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South)
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…
Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Elodie de Bock¹, Corrado Bernasconi², Tan P. Pham¹, Ana Maria Rodriguez³, Khaled Sarsour⁴, J. Michael Nebesky² and Christine de la Loge¹, ¹Mapi, Lyon, France, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Patients Like Me (PLM), Cambridge, MA, ⁴Genentech, South San Francisco, CA
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…
Abstract Number: 920 • 2017 ACR/ARHP Annual Meeting
Area-Level Predictors of Medication Nonadherence Among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study
Candace H. Feldman¹, Karen H. Costenbader², Daniel H. Solomon³, S.V. Subramanian⁴ and Ichiro Kawachi⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA
Background/Purpose: Among lupus patients, adherence to hydroxychloroquine (HCQ), the backbone of therapy, remains suboptimal. Individual-level factors, including younger age, poverty, and black race, have been…
Abstract Number: 1231 • 2017 ACR/ARHP Annual Meeting
Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence
Ayano Kelly^1,2,3,4, Daniel Sumpton^3,5,6, Clare O'Sullivan², Alexa Meara⁷, Robby Nieuwlaat⁸, Peter Tugwell^9,10,11, Lyn March^12,13,14, Allison Tong^3,6, Karine Toupin-April¹⁵, Francois Nantel¹⁶, B.J.F. Van den Bemt (PharmD, PhD)^17,18, Mary De Vera¹⁹, Vicki Evans²⁰, Willemina Campbell²¹, Peter Wong²², Rebecca Davey²³, Dorcas Beaton^24,25,26, Maria Suarez-Almazor^27,28,29,30, Geraldine Hassett^31,32, Helen I. Keen^33,34,35, Therese Dawson³⁶, Luke Crimston-Smith³⁷ and Kathleen Tymms³⁸, ¹Rheumatology, Canberra Rheumatology, Canberra, Australia, ²Rheumatology, The Canberra Hospital, Canberra, Australia, ³Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, ⁴School of Medicine, Australian National University, Canberra, Australia, ⁵Department of Rheumatology, Concord Hospital, Sydney, Australia, ⁶Sydney School of Public Health, University of Sydney, Sydney, Australia, ⁷Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁸Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, ⁹Center For Global Health, Institute of Population Health, Ottawa, ON, Canada, ¹⁰Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada, ¹¹Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ¹²Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹⁴Rheumatology, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, ¹⁵Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁷Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ¹⁸Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁹Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, ²⁰Clear Vision Consulting, Canberra, Australia, ²¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²²Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ²³Arthritis ACT, Canberra, Australia, ²⁴Research, Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada, ²⁵Scientist, Institute for Work & Health, Toronto, ON, Canada, ²⁶Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ²⁷GIM, AT & EC, UT MD Anderson Cancer Center, Houston, TX, ²⁸Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²⁹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,, The University of Texas MD Anderson Cancer Center, Houston, TX, ³⁰The University of Texas MD Anderson Cancer Center, Houston, TX, ³¹Rheumatology, Liverpool Hospital, Sydney, Australia, ³²Ingham Institute, Sydney, Australia, ³³Rheumatology, Royal Perth Hospital, Perth, Australia, ³⁴Leeds, Leeds, United Kingdom, ³⁵School of Medicine and Pharmacology, University of Western Australia, Perth, Australia, ³⁶Rheumatology, Lord Street Specialist Centre, Port Macquarie, Australia, ³⁷Australian National University, Canberra, Australia, ³⁸ANU, Canberra, Australia
Background/Purpose: Poor medication adherence attenuates optimal clinical benefits and reduces the overall effectiveness of health systems. A large number of interventions targeting medication adherence have…
Abstract Number: 1244 • 2017 ACR/ARHP Annual Meeting
Are Chinese-American Rheumatology Patients Who Use Traditional Chinese Medicine Less Adherent to Prescribed Western Medications?
Kai Sun¹, Jackie Szymonifka², Henghe Tian³, Ya Ju Chang⁴, Jennifer Leng⁵ and Lisa A. Mandl⁶, ¹Hospital for Special Surgery/Weill Cornell medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Internal Medicine, New York University School of Medicine, New York, NY, ⁴Mount Sinai Beth Israel, New York, NY, ⁵Immigrant Health and Cancer Disparities laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, ⁶Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: High adherence is crucial for the management of rheumatic diseases. Nonadherence is more common among immigrants and minorities and may contribute to known outcome…
Abstract Number: 30 • 2017 Pediatric Rheumatology Symposium
Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus
Alaina M. Davis¹, T. Brent Graham¹, Yuwei Zhu² and Melissa L. McPheeters³, ¹Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ²Biostatistics, Vanderbilt University, Department of Biostatistics, Nashville, TN, ³Health Policy, Vanderbilt University Medical Center, Department of Health Policy, Nashville, TN
Background/Purpose: The objectives of this study were to estimate prevalence of depression and medication non-adherence, describe demographic and disease characteristics associated with depression and medication…
Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Kelly Wise¹, Dustin Lewis², Bethanne Thomas², Karla Jones³, Stephanie Lemle², Darby MacDonald², Fatima Barbar-Smiley², Vidya Sivaraman² and Cagri Yildirim-Toruner³, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes. Biologics,…
Abstract Number: 1260 • 2016 ACR/ARHP Annual Meeting
Association of Traditional Chinese Medicine Use and Adherence to Prescribed Western Medications in Chinese-American Rheumatology Patients
Kai Sun¹, Henghe Tian², Yuo-Yu Lee³, Jennifer Leng⁴ and Lisa Mandl⁵, ¹Internal Medicine, Hospital for Special Surgery, New York, NY, ²Internal Medicine, New York University School of Medicine, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Immigrant Health and Cancer Disparities laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Chinese-Americans are one of the fastest growing immigrant groups in the US. They often use Traditional Chinese Medicine (TCM), but whether that affects medication…
Abstract Number: 1737 • 2016 ACR/ARHP Annual Meeting
Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital
Catalina Gómez-Arango¹, M. Luz García-Vivar¹, Montserrat Alonso-Diez², M. Milagros Alvarez-Lavin², Eva Galindez-Agirregoikoa³, Olaia Fernández-Berrizbeitia³, Esther Ruíz-Lucea¹, Juan María Blanco-Madrigal¹, Jose Francisco Garcia-Llorente¹, Lidia Estopiñán-Fortea³, Ignacio Torre-Salaberri⁴, Edurne Guerrero-Basterretxea³, Itziar Calvo-Zorrilla³, Amaia Bilbao-González⁵ and Natalia Rivera-García⁵, ¹Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ²Pharmacy Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁴Rheumaytology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁵Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Rheumatic inflammatory arthropaties such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthrities (SpA) are chronic diseases that require adequate therapies, sometimes biological drugs,…
Abstract Number: 2010 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares
Nathalie Costedoat-Chalumeau¹, Frédéric A. Houssiau², Peter M. Izmirly³, Véronique Le Guern⁴, Sandra V. Navarra⁵, Meenakshi Jolly⁶, Guillermo RUIZ-IRASTORZA⁷, Eric Hachulla⁸, Nancy Agmon-Levin⁹, Yehuda Shoenfeld¹⁰, Francesca Dall'Ara¹¹, Jill P. Buyon¹², Christophe Deligny¹³, Ricard Cervera¹⁴, Estibaliz Lazaro¹⁵, Holy Bezanahary¹⁶, Gabriel Baron¹⁷, Gaëlle Leroux¹⁸, Nathalie Morel⁴, Jean-Francois Viallard¹⁹, Christian Pineau²⁰, Lionel Galicier²¹, Ronald van Vollenhoven²², Angela Tincani²³, Hanh Nguyen²⁴, Guillaume Gondran²⁵, Noel Zahr²⁶, Jacques Pouchot²⁷, Jean Charles Piette²⁸, Michelle Petri²⁹ and David A. Isenberg³⁰, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ³New York University School of Medicine, New York, NY, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁶Rush, Chicago, IL, ⁷Cruces University Hospital, Barakaldo, Spain, ⁸Internal Medicine, Lille University Hospital, Lille, France, ⁹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel, ¹⁰Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ¹¹University of Pavia, Pavia, Italy, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁴Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ¹⁵Centre François Magendie, CHU de Bordeaux, Pessac, France, ¹⁶Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁷Hôpital Hôtel Dieu, Paris, France, ¹⁸Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ¹⁹Internal Medecine, Haut Lévèque Hospital, Bordeaux, France, ²⁰Rheumatology, MUHC, Montreal, QC, Canada, ²¹Clinical Immunology, St Louis Hospital, Paris, France, ²²Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²⁴Centre of Rheumatology. Medicine., University College of London Hospital, london, United Kingdom, ²⁵Internal Medicine Department, Limoges, France, ²⁶Pitié Salpêtrière, Pharmacological, Pitié Salpêtrière, Paris, France, ²⁷Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ²⁸Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ²⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁰Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Non-adherence to treatment, a major cause of continued lupus activity and flares, may be difficult to recognize. In this international prospective study, we evaluated…
Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 2254 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Laurent Chanroux, Fara Mboge and Denise Baldock, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologic agents (bDMARDs) have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim of our research…
Abstract Number: 2532 • 2016 ACR/ARHP Annual Meeting
Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis
Bo Katic¹, Ana Maria Rodriguez¹, Chris Curran¹, Michel Brethous², Corrado Bernasconi², Jan Michael Nebesky² and William Reiss³, ¹Patients Like Me (PLM), Cambridge, MA, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Genentech, South San Francisco, CA
Background/Purpose: US-based adult patients self-reporting RA were recruited from an online health-sharing network, PatientsLikeMe. Patients were invited to fill out a cross-sectional Web-based survey if…
Abstract Number: 322 • 2016 ACR/ARHP Annual Meeting
The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort
Maria I. Danila¹, Ryan C. Outman¹, Elizabeth J. Rahn², Amy S. Mudano³, David T. Redden⁴, Peng Li⁴, Fred A. Anderson⁵, Julia P. Anderson⁶, Susan L. Greenspan⁷, Andrea Z. LaCroix^6,8, Jeri W. Nieves⁹, Stuart L. Silverman¹⁰, Ethel S. Siris¹¹, Nelson B. Watts¹², Michael J. Miller¹³, Jeffrey R. Curtis¹⁴, Amy H. Warriner³, Nicole C. Wright¹⁵ and Kenneth G. Saag¹⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Group Health Cooperative, Seattle, WA, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of California San Diego, La Jolla, CA, ⁹Helen Hayes, West Haverstraw, NY, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Columbia University Medical Center, New York, NY, ¹²Endocrinology, Diabetes & Metabolism, University of Cincinnati, Cincinnati, OH, ¹³University of Oklahoma, Tulsa, OK, ¹⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To improve the rate of osteoporosis medication use in women with a prior fracture we developed and implemented a tailored, educational, direct-to-patient video intervention…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.